NCT04174599 2025-04-20
Study to Compare the Efficacy and Safety of F-627 and GRAN®
EVIVE Biotechnology
Phase 3 Completed
Clinical Trials
9 trialsNCT03343145 2020-12-28
A Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients
Dong-A ST Co., Ltd.
Phase 3 Completed
NCT02685111 2020-07-31
Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
Asan Medical Center
Phase 2 Terminated
NCT00002866 2020-04-01
Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 1 Completed
NCT01569087 2016-12-05
Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer
Biocad
Phase 2 Completed
NCT02104830 2016-10-24
Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients
Biocad
Phase 3 Completed
NCT01519700 2015-05-06
PIONEER
Sandoz
Phase 3 Completed
NCT00030758 2013-08-07
Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer
National Cancer Institute (NCI)
Phase 4 Unknown
NCT00771433 2011-05-13
G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed